Molecular insights, particularly the duplication of the T gene (brachyury) and alterations in CDKN2A/B, EGFR, and chromatin remodeling genes, have paved the way for targeted therapies, highlighting the potential of personalized medicine in improving chordoma treatment paradigms and reserving aggressive surgery for only the most advanced cases [14,15]. This evidence concerns the gene EGFR and chordoma.